Related Experiment Video
Updated: Feb 22, 2026
Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations
Published on: March 29, 2017
BACH2 promotes indolent clinical presentation in Waldenström macroglobulinemia
Charles Herbaux1,2, Elisabeth Bertrand1, Guillemette Marot3
1Inserm U837, Team 3, Cancer Research Institute of Lille, Lille, France.
Abstract:
Approximately 30% of the patients who fulfil the criteria of Waldenström's macroglobulinemia (WM) are diagnosed while asymptomatic (indolent), and will not require immediate therapy. Conversely, patients with a disease-related event will be considered for therapy. The physiopathology of these 2 groups remains unclear, and the mechanisms of progression from indolent to symptomatic WM have yet to be fully understood. Seventeen patients diagnosed with WM were included in this study, 8 asymptomatic WM (A-WM) and 9 symptomatic WM (S-WM). A differential analysis was performed on a first series of 11 patients and identified 48 genes whose expression separated samples from A- to S-WM. This gene signature was then confirmed on a second independent validation set of 6 WM. Within this expression profile, BACH2, a B-cell transcription factor known to be a tumor suppressor gene, was found to be over-expressed in A-MW relatively to S-MW. We specifically over-expressed BACH2 in a WM-related cell line and observed a significant reduction of the clonogenic activity. To the best of our knowledge, we report for the first time a specific gene expression signature that differentiates A-WM and S-WM. Within this expression profile, BACH2 was identified as a candidate gene that may help to understand better the behavior of tumor cells in indolent WM.
Insights
This study identifies a gene expression signature differentiating asymptomatic and symptomatic Waldenström's macroglobulinemia (WM). Over-expression of the tumor suppressor gene BACH2 in asymptomatic WM suggests its role in disease behavior.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Waldenström's macroglobulinemia (WM) presents in both asymptomatic (indolent) and symptomatic forms, with distinct therapeutic needs.
- The underlying pathophysiology and progression mechanisms from indolent to symptomatic WM remain poorly understood.
- Identifying molecular differences between these WM subtypes is crucial for understanding disease behavior.
Purpose of the Study:
- To identify a gene expression signature that distinguishes asymptomatic WM (A-WM) from symptomatic WM (S-WM).
- To investigate the role of specific genes within this signature, particularly BACH2, in WM pathophysiology.
- To provide insights into the molecular mechanisms driving WM progression.
Main Methods:
- Differential gene expression analysis was performed on patient samples from A-WM and S-WM cohorts.
- A gene signature differentiating the two groups was identified and validated in an independent cohort.
- The function of the identified gene BACH2 was investigated in a WM-related cell line.
Main Results:
- A distinct gene expression signature comprising 48 genes was identified, differentiating A-WM from S-WM.
- The tumor suppressor gene BACH2 was found to be significantly over-expressed in A-WM compared to S-WM.
- Experimental over-expression of BACH2 in a WM cell line led to a significant reduction in clonogenic activity.
Conclusions:
- A novel gene expression signature can differentiate between asymptomatic and symptomatic Waldenström's macroglobulinemia.
- BACH2 is identified as a key candidate gene within this signature, potentially playing a role in regulating WM cell behavior.
- These findings offer new avenues for understanding WM progression and developing targeted therapeutic strategies.
